General aspects of multiple sclerosis and perspectives on disease prognosis
Aspectos gerais da esclerose múltipla e perspectivas para o prognóstico da doença
Resumo
Multiple sclerosis, a chronic, inflammatory, autoimmune disease affecting the central nervous system, exhibits varying progression, characterized by relapses and remissions of symptoms. This study discusses its broad aspects, from epidemiology to prognosis. Utilizing a narrative review, recent data from platforms like PubMed, BVS, Scielo, and LILACS were compiled. The disease impacts patients significantly, often causing disability, especially among young adults. Classified into four clinical forms, therapies differ per patient based on their condition. These include corticosteroids, disease-modifying drugs, and symptom-specific treatments, aiming to improve quality of life. However, these treatments are costly, impacting patients and healthcare systems. Multiple sclerosis leads to cognitive and physical disabilities, imposing financial burdens for care. Recent studies offer hope for better interventions, but further research is essential for impactful treatments.
Downloads
Referências
AMIN, M.; HERSH, C.M. Updates and advances in Multiple sclerosis neurotherapeutics. Neurodegener Dis Manag., v.13; n.1, p. 47-70, 2023.
ASSOCIAÇÃO BRASILEIRA DE ESCLEROSE MÚLTIPLA. Esclerose Múltipla em detalhes. São Paulo: ABEM, 2021. Ebook.
BIANCO, J. et al. Prevalência da esclerose múltipla em pacientes tratados com medicamentos modificadores do curso da doença utilizando dados do Sistema Único de Saúde brasileiro. Jornal Brasileiro de Economia e Saúde, v. 15(1), p. 12-23, 2023.
BENEDICT, R.H.B.; AMATO, M.P.; DELUCA, J.; GEURTS, J.J.G. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol., v. 19(10), p. 860-871, 2020.
BRANDÃO, P.M.F. et al. Age, motor dysfuntion and neuropsychiatric symptoms impact quality of life in multiple sclerosis. Rev Bras Enferm., v.75, n.6, 2022.
DOBSON, R.; GIOVANNONI, G. Multiple sclerosis – a review. European Journal of Neurology, v. 26(1), p. 27-40, 2018.
FEDERAÇÃO INTERNACIONAL DA ESCLEROSE MÚLTIPLA. Atlas de EM – Parte 1: Mapeando a Esclerose Múltipla pelo Mundo – principais descobertas epidemiológicas. 3ª ed. Organização Mundial de Saúde: ABEM, 2020.
KIM, Y.; KRAUSE T.M.; BLUM, P.; FREEMAN, L. Disease modifying therapies continue to drive up healthcare cost among individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders, v. 30, p. 69-75, 2019.
LEAL, A.G.; AGUIAR, P.H.P.; RAMINA, R. Tratado de Neurologia Clínica e Cirúrgica. Academia Brasileira de Neurocirurgia. Ponta Grossa, PR: Atenas, 1 ed., 2022.
LEBRUN-FRÉNAY, C. et al. The radiologically isolated syndrome: revisei diagnostic criteria. Brain, v. 146, n.8, p. 3431-3443, 2023.
LIU, R. et al. Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. Frontiers in Immunology, 2022.
LOUIS, E.D.; MAYER, S.A.; ROWLAND, L.P. Merrit: Tratado de Neurologia. 13 ed. Rio de Janeiro: Guanabara Koogan, 2018.
LUBLIN, F.D. et al. How patients with multiple sclerosis acquire desability. Brain, v. 145(9), p. 3147-3161, 2022.
MINISTÉRIO DA SAÚDE. Protocolo Clínico e Diretrizes Terapêuticas: Esclerose Múltipla – Relatório de Recomendação. Brasília: CONITEC, 2019.
MULTIPLE SCLEROSIS INTERNATIONAL FEDERATION. Atlas of MS – part 2: clinical management of multiple sclerosis around the world. 3ª de. ABEM, 2021.
NASERI, A. et al. Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis. Mult Scler Relat Disord, 2021.
NOURBAKHSH, B.; MOWRY, E.M. Multiple Sclerosis Risk Factors and Patoghenesis. Adcademy of Neurology. Continuum, v.25, n.3, p. 596-610, 2019.
ORHUN, H.; KANTARCI, M.D. Phases and Phenotypes of Multiple Sclerosis. American of Neurology. Continuum, v. 25, n.3, p. 636-654, 2019.
RUIZ, F.; VIGNE, S.; POT, E. Resolution of inflammation during Multiple sclerosis. Semin Immunopathol., v. 41, n.6, p. 711-726, 2019.
SILVA, N.L.; TAKEMOTO, M.L.S.; BOULOS, F.C. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study. BMC Health Services Research, v. 16(102), 2016.
SILVA, T.C. et al. Prevalence of nursing diagnosis Impaired Physical Mobility in people with multiple sclerosis. Rio de Janeiro: Revista de Enfermagem, 2019.
SHAO, H.; STOEKER, C.; MONNETTE, A. M.; SHI, L. Cost Sharing of Disease – Modifying Treatments (DMTs) as Policy Lever to Improve DMTs’ Acess in Multiple Sclerosis. Value in health journal, v. 21(9), p. 1083-1089, 2018.
TAUIL, C.B. et al. Fom Charcot`s descriptions to the current understending of neuropsychiatrc symptons in multiple sclerosis. Arq Neuropsquia., v.77, n.7, p. 521-524, 2019.
TRAVERS, B.S.; TSANG, B.K.; BARTON, J.L. Multiple sclerosis: Diagnosis, disease-modifying therapy and prognosis. AJGP, v. 51(4), 2022.
